Published in Transplant Proc on October 01, 1994
Bone marrow augmentation of donor-cell chimerism in kidney, liver, heart, and pancreas islet transplantation. Lancet (1994) 5.54
Outcome analysis of 71 clinical intestinal transplantations. Ann Surg (1995) 2.95
Clinical intestinal transplantation: new perspectives and immunologic considerations. J Am Coll Surg (1998) 2.31
Weaning of immunosuppression in long-term liver transplant recipients. Transplantation (1995) 1.59
Clinical intestinal transplantation: a decade of experience at a single center. Ann Surg (2001) 1.44
Current status of intestinal transplantation in children. J Pediatr Surg (1998) 1.28
The two-way paradigm of transplantation immunology. Clin Immunol Immunopathol (1996) 0.78
Immunological considerations in in utero hematopoetic stem cell transplantation (IUHCT). Front Pharmacol (2015) 0.75
The changing immunology of organ transplantation. Hosp Pract (1995) (1995) 0.75
The bidirectional paradigm of transplant immunology. Ann N Y Acad Sci (1995) 0.75
Actively acquired tolerance of foreign cells. Nature (1953) 19.82
Cell migration, chimerism, and graft acceptance. Lancet (1992) 12.24
Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology (1993) 8.76
THE REVERSAL OF REJECTION IN HUMAN RENAL HOMOGRAFTS WITH SUBSEQUENT DEVELOPMENT OF HOMOGRAFT TOLERANCE. Surg Gynecol Obstet (1963) 8.04
Long survival in rats after multivisceral versus isolated small-bowel allotransplantation under FK 506. Surgery (1991) 5.92
Bone marrow augmentation of donor-cell chimerism in kidney, liver, heart, and pancreas islet transplantation. Lancet (1994) 5.54
Identification of proliferating dendritic cell precursors in mouse blood. J Exp Med (1992) 5.03
Intestinal transplantation in composite visceral grafts or alone. Ann Surg (1992) 4.96
Murine liver allograft transplantation: tolerance and donor cell chimerism. Hepatology (1994) 4.32
Donor cell chimerism permitted by immunosuppressive drugs: a new view of organ transplantation. Immunol Today (1993) 4.29
Replacement of donor lymphoid tissue in small-bowel transplants. Lancet (1991) 3.85
Systemic chimerism in human female recipients of male livers. Lancet (1992) 3.63
Chimerism after liver transplantation for type IV glycogen storage disease and type 1 Gaucher's disease. N Engl J Med (1993) 3.36
Chimerism and donor-specific nonreactivity 27 to 29 years after kidney allotransplantation. Transplantation (1993) 3.13
Hematolymphoid cell trafficking, microchimerism, and GVH reactions after liver, bone marrow, and heart transplantation. Transplant Proc (1993) 2.81
Studies of homograft sex and of gamma globulin phenotypes after orthotopic homotransplantation of the human liver. Surg Forum (1969) 2.80
Long-term results of a controlled prospective study with transfusion of donor-specific bone marrow in 57 cadaveric renal allograft recipients. Transplantation (1991) 2.32
Possible active enhancement of a human cadaver renal allograft with antilymphocyte serum (ALS) and donor bone marrow: case report of an initial attempt. Surgery (1976) 1.84
Long-term (25-year) survival after renal homotransplantation--the world experience. Transplant Proc (1990) 1.26
Donor-specific bone marrow infusion after orthotopic liver transplantation. Lancet (1994) 1.18
A seven-year experience with donor-specific blood transfusions. Results and considerations for maximum efficacy. Transplantation (1985) 1.17
Evidence that peritoneal exudate cells cultured with eye-derived fluids are the proximate antigen-presenting cells in immune deviation of the ocular type. J Immunol (1993) 1.15
HLA matching and the point system. Clin Transplant (1993) 0.80
FK 506 for liver, kidney, and pancreas transplantation. Lancet (1989) 13.70
Cell migration, chimerism, and graft acceptance. Lancet (1992) 12.24
The Banff 97 working classification of renal allograft pathology. Kidney Int (1999) 9.02
Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology (1993) 8.76
Bone marrow as a potential source of hepatic oval cells. Science (1999) 8.52
Long survival in rats after multivisceral versus isolated small-bowel allotransplantation under FK 506. Surgery (1991) 5.92
Bone marrow augmentation of donor-cell chimerism in kidney, liver, heart, and pancreas islet transplantation. Lancet (1994) 5.54
Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant (2007) 5.39
Prokaryotic regulation of epithelial responses by inhibition of IkappaB-alpha ubiquitination. Science (2000) 5.38
Liver, kidney, and thoracic organ transplantation under FK 506. Ann Surg (1990) 5.01
Liver transplantation (1). N Engl J Med (1989) 4.53
Murine liver allograft transplantation: tolerance and donor cell chimerism. Hepatology (1994) 4.32
Donor cell chimerism permitted by immunosuppressive drugs: a new view of organ transplantation. Immunol Today (1993) 4.29
Pancreatic islet transplantation after upper abdominal exenteration and liver replacement. Lancet (1990) 4.18
Baboon-to-human liver transplantation. Lancet (1993) 4.01
Systemic chimerism in human female recipients of male livers. Lancet (1992) 3.63
Variable chimerism, graft-versus-host disease, and tolerance after different kinds of cell and whole organ transplantation from Lewis to brown Norway rats. Transplantation (1995) 3.63
Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg (1991) 3.57
Canine kidney transplantation with FK-506 alone or in combination with cyclosporine and steroids. Transplant Proc (1987) 3.55
Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant (2014) 3.43
Chimerism after liver transplantation for type IV glycogen storage disease and type 1 Gaucher's disease. N Engl J Med (1993) 3.36
Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology (1991) 3.34
Early trials with FK 506 as primary treatment in liver transplantation. Transplant Proc (1990) 3.29
Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant (2010) 3.29
Use of OKT3 with cyclosporin and steroids for reversal of acute kidney and liver allograft rejection. Nephron (1987) 3.26
The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am J Pathol (1988) 3.24
Rejection of multivisceral allografts in rats: a sequential analysis with comparison to isolated orthotopic small-bowel and liver grafts. Surgery (1990) 3.18
Renal transplantation in baboons under FK 506. Surgery (1989) 3.17
Dendritic cell loss from nonlymphoid tissues after systemic administration of lipopolysaccharide, tumor necrosis factor, and interleukin 1. J Exp Med (1995) 3.16
Pathology of hepatic transplantation: A review of 62 adult allograft recipients immunosuppressed with a cyclosporine/steroid regimen. Am J Pathol (1985) 3.16
Chimerism and donor-specific nonreactivity 27 to 29 years after kidney allotransplantation. Transplantation (1993) 3.13
Orthotopic liver transplantation in dogs receiving FK-506. Transplant Proc (1987) 3.11
Expression of Epstein-Barr virus-encoded small RNA (by the EBER-1 gene) in liver specimens from transplant recipients with post-transplantation lymphoproliferative disease. N Engl J Med (1992) 2.98
Outcome analysis of 71 clinical intestinal transplantations. Ann Surg (1995) 2.95
Liver transplantation (2). N Engl J Med (1989) 2.93
Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha. Circ Res (1997) 2.91
Long-term survival after liver transplantation in 4,000 consecutive patients at a single center. Ann Surg (2000) 2.91
Functional characterization of infiltrating T lymphocytes in human hepatic allografts. Hum Immunol (1986) 2.84
Allospecificity of activated T cells grown from endomyocardial biopsies from heart transplant patients. Transplantation (1986) 2.82
The lost chord: microchimerism and allograft survival. Immunol Today (1996) 2.81
Hematolymphoid cell trafficking, microchimerism, and GVH reactions after liver, bone marrow, and heart transplantation. Transplant Proc (1993) 2.81
FK 506: an immunosuppressant for the 1990s? Lancet (1991) 2.80
Cadaveric small bowel and small bowel-liver transplantation in humans. Transplantation (1992) 2.75
THE IMMUNOSUPPRESSIVE EFFECTS OF FR 900506 IN RATS RECEIVING HETEROTOPIC CARDIAC ALLOGRAFTS. Surg Res Commun (1987) 2.75
Detection of Y chromosome sequences in Turner's syndrome by Southern blot analysis of amplified DNA. Lancet (1993) 2.65
A review of adult and pediatric post-transplant liver pathology. Pathol Annu (1987) 2.62
FK506 "rescue" for resistant rejection of renal allografts under primary cyclosporine immunosuppression. Transplantation (1994) 2.50
Evidence for a role of IL-17 in organ allograft rejection: IL-17 promotes the functional differentiation of dendritic cell progenitors. J Immunol (1999) 2.48
Propagation of dendritic cell progenitors from normal mouse liver using granulocyte/macrophage colony-stimulating factor and their maturational development in the presence of type-1 collagen. J Exp Med (1994) 2.48
Comprehensive assessment and standardization of solid phase multiplex-bead arrays for the detection of antibodies to HLA. Am J Transplant (2013) 2.45
Toxicology of FK-506 in the Lewis rat. Transplant Proc (1987) 2.37
Clinical intestinal transplantation: new perspectives and immunologic considerations. J Am Coll Surg (1998) 2.31
Pigmented villonodular synovitis (giant-cell tumor of the tendon sheath and synovial membrane). A review of eighty-one cases. J Bone Joint Surg Am (1984) 2.31
FK 506 in clinical kidney transplantation. Transplant Proc (1991) 2.29
Differential survival of hamster-to-rat liver and cardiac xenografts under FK 506 immunosuppression. Transplant Proc (1991) 2.28
Banff 2011 Meeting report: new concepts in antibody-mediated rejection. Am J Transplant (2012) 2.28
Assessment of five-year experience with abdominal organ cluster transplantation. J Am Coll Surg (1995) 2.25
Evidence for superantigen involvement in insulin-dependent diabetes mellitus aetiology. Nature (1994) 2.25
Should HLA mismatch acceptability for sensitized transplant candidates be determined at the high-resolution rather than the antigen level? Am J Transplant (2015) 2.24
Human islet isolation and allotransplantation in 22 consecutive cases. Transplantation (1992) 2.20
Transplantation milestones. Viewed with one- and two-way paradigms of tolerance. JAMA (1995) 2.20
FK-506--how much potential? Immunol Today (1989) 2.20
Aspartic acid at position 57 of the HLA-DQ beta chain protects against type I diabetes: a family study. Proc Natl Acad Sci U S A (1988) 2.19
Hamster-to-rat heart and liver xenotransplantation with FK506 plus antiproliferative drugs. Transplantation (1993) 2.17
A critical appraisal of methods to grade transplant glomerulitis in renal allograft biopsies. Am J Transplant (2010) 2.14
Graft-versus-host disease after brown Norway-to-Lewis and Lewis-to-Brown Norway rat intestinal transplantation under FK506. Transplantation (1993) 2.14
Wnt-5a has tumor suppressor activity in thyroid carcinoma. Oncogene (2005) 2.11
Modulation of nitrogen oxide synthesis in vivo: NG-monomethyl-L-arginine inhibits endotoxin-induced nitrate/nitrate biosynthesis while promoting hepatic damage. J Leukoc Biol (1990) 2.11
One hundred ten consecutive primary orthotopic liver transplants under FK 506 in adults. Transplant Proc (1991) 2.10
A prospective randomized trial of FK506-based immunosuppression after renal transplantation. Transplantation (1995) 2.09
Trajectories of alcohol consumption following liver transplantation. Am J Transplant (2010) 2.01